New combo targets Hard-to-Treat myeloma spread

NCT ID NCT04166565

NEW Ongoing Disease control Sponsor: Stichting European Myeloma Network Source: ClinicalTrials.gov ↗

First seen May 01, 2026 · Last updated May 01, 2026

Summary

This study tests a combination of four drugs (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) in 41 people with multiple myeloma that has spread to other organs like skin, liver, or lungs. The goal is to see if this treatment can shrink or control the cancer. Participants will be followed for up to 5 years to monitor side effects and how long the response lasts.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Ankara University

Ankara, Turkey (Türkiye)
Anticancer Hospital of Thessaloniki

Thessaloniki, Greece
Dokuz Eylul University

Balçova, Turkey (Türkiye)
Erciyes University

Kayseri, Turkey (Türkiye)
Marmara University

Pendik, Turkey (Türkiye)
Univerity of Turin

Torino, Italy
University of Athens

Athens, Greece
University of Bologna

Bologna, Italy

Conditions

Explore the condition pages connected to this study.

EXTRAMEDULLARY PLASMACYTOMA MULTIPLE MYELOMA